BioSpace News Archive

Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced the initiation of a Phase 2 clinical trial of Assembly Bio’s investigational hepatitis B virus (HBV) core inhibitor candidate

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, March 4, 2021.

Molecular Templates, Inc. announced that it will present and participate in 1-on-1 investor meetings at the Cowen 41st Annual Health Care Conference, the Barclays Global Healthcare Conference and the Oppenheimer 31st Annual Healthcare Conference.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the appointment of Daniel Dolan as Chief Financial Officer (CFO), effective close of business March 12, 2021.

HTG Molecular Diagnostics, Inc., a life science company whose mission is to advance precision medicine, announced it has completed its feasibility testing for a planned whole transcriptome panel using the HTG EdgeSeq technology, and has released a follow-on whole transcriptome product white paper, regarding the performance of a prototype panel for multiple cancer indications compared to RNA sequencing.

Slayback Pharma LLC, a Princeton, NJ based specialty pharmaceutical company, announced the appointment of Paul Campanelli to its Board of Directors.

RaySearch Laboratories AB announces that Royal Brisbane and Women’s Hospital has treated its first patients using the RayStation® treatment planning system in combination with Varian iX** linacs

Graystone Company, Inc. (OTC: GYST) announced today that it has completed the reverse merger with NutraGyst, Inc.

Positive full results from the pivotal NAVIGATOR Phase III trial showed AstraZeneca and Amgen’s tezepelumab demonstrated a statistically significant and clinically meaningful1 reduction in the annualized asthma exacerbation rate (AAER) in severe, uncontrolled asthma patients

The testing site is located within the Greater Toronto Area that has one of the highest positivity rates in Ontario.